SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026

Image File

Original HTML

MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ketone and combined monitoring; "Act Earlier: From Insight to Intervention," exploring multimodal sensing and insulin delivery; and "Go Further: Realizing the Unimagined," looking toward broader biosensing applications.

The vision was further explored at the SiBionics industry symposium, "From Sensors to Integrated Care: Emerging Technologies Shaping the Future of Diabetes Management." The symposium was chaired by Prof. Mark Evans, of the University of Cambridge and Cambridge University Hospitals, United Kingdom, and Dr. Guido Freckmann, of the Institute for Diabetes-Technology GmbH (IfDT), Germany.

Prof. Karolina Kędzierska-Kapuza discussed CGM and individualized care in type 3c diabetes. Prof. Wei Qiang presented CGM accuracy findings and future multimodal sensing concepts. Prof. Andrej Janež explored continuous ketone monitoring in the GLP-1 era. Prof. Ahmad Haidar presented ketone monitoring research and the first findings of the SMART02 feasibility study on integrated glucose sensing and insulin delivery.

SMART02 evaluated an early prototype of niia signature, an investigational device jointly developed by PharmaSens and SiBionics since the two companies announced their collaboration in June 2025. niia signature will combine continuous glucose monitoring (CGM), insulin delivery and an automated glucose control (AGC) algorithm in one wearable patch. It aims to reduce the burden of managing separate devices for automated insulin delivery (AID).

The study addressed a central integration challenge: maintaining glucose measurement performance when insulin is delivered close to the sensor. Temporary interference after a bolus was uncommon overall and occurred mainly with doses of 10 units or more, where the probability was 20 to 25%. On average, the sensor signal fully recovered approximately 20 minutes after bolus delivery. In the second part of the study, the prototype was also tested together with the AGC algorithm developed by Prof. Ahmad Haidar. The PharmaSens niia patch pump, the SiBionics sensor and the AGC algorithm performed consistently throughout the study. The findings, also featured at the SiBionics booth, mark an early development milestone.

Together, the exhibition and symposium connected clinical needs with emerging technologies. Through niia signature, PharmaSens and SiBionics are exploring how integration could make future AID easier to wear and use. Further research is needed to establish its performance and clinical potential.

niia signature is an investigational device. It is not approved or cleared in any market and is not available for sale.

About SIBIONICS

Founded in 2015 and headquartered in Shenzhen, SiBionics is a medical technology company specializing in CGM and multi-parameter health solutions, with nearly 700 professionals worldwide. Combining advanced sensor technology with AI-driven algorithms, the company develops accessible, reliable solutions for chronic disease management. Its multidisciplinary R&D team brings expertise in biosensing, chip design, materials science, and artificial intelligence, supporting innovation from research to commercialization. Through fully in-house CGM systems and continuous monitoring technologies, SiBionics provides real-time data and comprehensive insights to support daily management and better-informed health decisions. Learn more at www.sibionicscgm.com.

About PharmaSens

PharmaSens AG, a privately owned Swiss company, is dedicated to simplifying diabetes management and broadening the reach of insulin pump therapy. The PharmaSens team has a wealth of experience in diabetes care and medtech device engineering, having contributed to the development of multiple insulin pump generations. Over several years of research and development, PharmaSens has built a patented international portfolio of distinctive and innovative products. For more information, please visit PharmaSens.com.

Media contacts

SIBIONICS: [email protected]

PharmaSens: [email protected]

Share this article

Class (B2B/B2C)

B2B

Ingest Status

Need Review

Dedupe hash

prn_302897720

Press Eligible

Yes

Press Eligible Reason

QA FAIL (need review): TARGET contains unsupported factual claims: 'before any regulatory submission' (not in SOURCE) and 'led by Prof. Ahmad Haidar' (SOURCE only says he presented the findings).

Source Name

Unknown Company

Original Summary

<p>MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering...</p>

Original Link

Original Source

Image URL

https://app.tiny-img.com/images/json-ld/d36bbb52f943584055cc33ce8c9e2ace.png

Generated Article_json

{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "SiBionics, PharmaSens Report SMART02 Data on Integrated Insulin Patch", "body_html": "<p><strong>Milan -- [CURRENT_DATE] --</strong> SiBionics and PharmaSens presented early feasibility data at the European Association for the Study of Diabetes (EASD) 2026 showing their jointly developed insulin-delivery patch maintained consistent sensor performance despite insulin interference risks, an engineering hurdle that has slowed integration of continuous glucose monitoring with automated insulin delivery.</p><h5>SMART02 study finds bolus interference mainly limited to high doses</h5><p>The feasibility study, led by Prof. Ahmad Haidar and presented at a SiBionics industry symposium, tested an early prototype of niia signature, a device combining continuous glucose monitoring, insulin delivery and an automated glucose control (AGC) algorithm in a single wearable patch. Temporary sensor interference after an insulin bolus occurred infrequently overall, with a 20% to 25% probability observed mainly at doses of 10 units or more. Sensor signal recovery averaged approximately 20 minutes following bolus delivery.</p><h5>Patch pump, sensor and algorithm run together in second study phase</h5><p>In the study's second phase, the PharmaSens niia patch pump, the SiBionics sensor and Prof. Haidar's AGC algorithm operated together, with the companies reporting consistent performance across the combined system throughout testing.</p><h5>Collaboration dates to June 2025 partnership announcement</h5><p>SiBionics and PharmaSens have worked on niia signature since announcing their partnership in June 2025, targeting a single-wearable alternative to the separate CGM and insulin-delivery devices currently required for automated insulin delivery (AID) systems. The companies describe the integration challenge of measuring glucose accurately while insulin is delivered in close proximity to the sensor as a central technical barrier the prototype needed to address.</p><h5>Device remains unapproved pending further clinical evaluation</h5><p>Niia signature is an investigational device not approved or cleared for sale in any market. SiBionics and PharmaSens said further research is required to establish its performance and clinical potential before any regulatory submission.</p><p>The companies also outlined a broader sensing roadmap at EASD under the theme \"See More, Act Earlier,", "meta_description": "SiBionics and PharmaSens report SMART02 feasibility data at EASD 2026 on an integrated CGM-insulin patch, with bolus interference mainly at doses above 10 units.", "seo_keywords": "SiBionics, PharmaSens, niia signature, EASD 2026, continuous glucose monitoring, automated insulin delivery, diabetes technology, SMART02 study", "companies": ["SiBionics", "PharmaSens"], "industries": ["Healthcare & Biotech"], "markets_regions": ["Europe", "Global"], "news_type": ["product_launch", "clinical_trial_update"], "products": ["niia signature"], "themes": ["medical_devices", "digital_transformation", "clinical_research"], "events": ["EASD 2026"], "cta_text": "Details on the SMART02 feasibility study and niia signature development were presented at EASD 2026 in Milan.", "learn_more": "https://www.sibionicscgm.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}

Content Hash (SHA-256, erste 32 hex)

584dea1d5eec74b2f2805f688131f648